CURRENT APPROACHES TO TREATMENT OF CHLAMYDIOSIS.
DOI:
https://doi.org/10.11603/24116-4944.2016.1.5992Keywords:
chlamydiosis, infection, treatment, microscopy.Abstract
In this paper there was investigated the effectiveness of the drugs Sumamed (azithromycin active ingredient), clarithromycin (macrolide antibiotic) chlamidiosis treatment. These data suggest that the drug Clarithromycin compared to Sumamed is a smaller percentage cured( according to PCR after 2 weeks of treatment, operty group is 93.3 %, in the second group – 96.6 %. Studies cure rates in 2 years according to the PCR results, 70 % of women І group and 93.3 % – II group had chlamydia. In patients who took the first drug, there was a higher percentage of adverse reactions and the recurrence rate is 4.,3 times higher than in patients who took sumamed. Therefore, taking into account the results of the study, we recommend that the treatment regimen selected for group II patients (etiotropic therapy drug Sumamed) because when using it is observed the best results of cure, adverse reactions almost never occur and the risk of relapse is minimized.References
Malova Y. A. Sovremennyy vz•hlyad na problemu urohenytalʹnoho khlamydyoza u devochek mladsheho vozrasta / Y. O. Malova // 1-y Sybyrskyy konhress akusherov-hynekolohov y dermatovenerolohov : materyaly konhressa. – Novosybyrsk. 2006. – S. 34–37.
Dmytryev H. A. Laboratornaya dyahnostyk a bakteryalʹnykh urohenytalʹnykh ynfektsyy / H. A. Dmytryev. – M. : Medytsynskaya knyha, 2003. – S. 330.
Mytrokhyn B. E. Oryhynalʹnye preparaty y dzheneryky: problemy vybora / B. E. Mytrokhyn // 1-y Sybyrskyy konhress akusherov-hynekolohov y dermatovenerolohov. – Novosy- byrsk, 2006. – S 41–43.
Éffektyvnostʹ novoy skhemy prymenenyya sumameda dlya lechenyya bolʹnykh s urohenytalʹnoy khlamydyynoy ynfektsyey / N. V. Kunhurov, N. M. Herasymova, N. Y. Skydan [y dr.] // YPPP. – 2002. – № 1. – S. 20–24.
Astsaturova O. R. Vulʹvovahynalʹnaya y khlamydyynaya ynfektsyy pry beremennosty / O. R. Astsaturova, A. P. Nykonov // Ynf. y antymykrob. terapyya. – 1999. – № 1 (3). – S. 72–76.
Harkness, tsyt. po: Morton R. S. Urohenytalʹnaya khlamydyynaya ynfektsyya: pereotsenka dannykh y hypotezy / R. S. Morton, Dzh. R. Kynhkhorn // YPPP. – 2000. – № 2. – S. 4–15.
Contact tracing in patients with genital chlamydial infection / Jones, Sollieha. Smith. I. Thelin [et al.] // Brit. J .Vener Dis. – 1980. – Vol. 56. – P. 259.
Schachter J. Are chlamydial infections the most prevalent venereal disease? / J. Schachter // JAMA. – 1975. – Vol. 231. – P. 1252.
Rasprostranennostʹ khlamydyynoy ynfektsyy y osobennosty seksualʹnoho povedenyya studentov / A. A. Khryanyn, O. V. Reshetnykov, S. V Lebedev [y dr.] // Tam zhe; s. 86.
Otdalennye rezulʹtaty lechenyya bolʹnykh oslozhnennymy formamy urohenytalʹnoho khlamydyoza azytromytsynom po skheme 1-7-14 / V. V. Chebotarev, N. V. Chebotareva, B. M. Kasymov, M. A. Homberh // YPPP. – 2003. – № 3. – S. 34–36.
Éffektyvnostʹ novoy skhemy prymenenyya sumameda dlya lechenyya bolʹnykh s urohenytalʹnoy khlamydyynoy ynfektsyey / N. V. Kunhurov, N. M. Herasymova, N. Y. Skydan [y dr.] // YPPP. – 2002. – № 1. – S. 20–24.
Dzhekobs M. Novye podkhody k optymyzatsyy antymykrobnoy terapyy ynfektsyy dykhatelʹnykh putey s yspolʹzovanyem farmakokynetycheskykh/farmakodynamycheskykh parametrov / M. Dzhekobs // Klyn. mykrobyol. y antymykrob. khymyoter. – 2014. – № 6 (1). – S. 22–31.
Lau C. Y. Azitromycin versus doxycyclme for genital chlamydial infections a meta-analysis of randomized clinical trials / C. Y. Lau, A. K. Qureshi // Sex Trans. Dis. – 2012. – Vol. 29 (9). – P. 497–502.
Bevan C. D. Efficacy and safety azitromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease / C. D. Bevan, G. L. Ridgway, C. D. Rothermel // J. Int. Med. Res. – 2013. – Vol. 31 (1). – P. 45–54.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish in this journal agree to the following terms:
1. The authors reserve the right to authorship of the work and pass the journal right of first publication of this work is licensed under a Creative Commons Attribution License, which allows others to freely distribute the work published with reference to the authors of the original work and the first publication of this magazine.
2. Authors are entitled to enter into a separate agreement on additional non-exclusive distribution of work in the form in which it was published in the magazine (eg work place in the electronic repository institution or publish monographs in part), provided that the reference to the first publication of this magazine.
3. Policy magazine allows and encourages authors placement on the Internet (eg, in storage facilities or on personal websites) manuscript of how to submit the manuscript to the editor and during his editorial processing, since it contributes to productive scientific discussion and positive impact on the efficiency and dynamics of citing published work (see. The Effect of Open Access).
